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ing information depending on the dosage regimen and
mode of investigation. Most investigators using early
graft angiography or ultrafast computed tomography
showed no difference between placebo and treatment
groups.11-14 In contrast, Van de Meyer and colleagues6
used graft angiography 1 year after the operation (non-
randomized retrospective study) and showed distal
anastomosis occlusion rates of 20.5% for aprotinin-
treated patients versus 12.7% for those without apro-
tinin (P = .09). The proportions of patients with occlud-
ed grafts were 44.1% versus 26.3%, respectively (P =
.3). Perioperative myocardial infarction occurred in
14.3% versus 7.0% (P = .12).
In an attempt to perform a definitive prospective ran-
domized study of vein graft patency, Bayer commis-
sioned a multicenter trial using graft angiography with-
in a few days of surgery. The patients were recruited
from 10 centers in the United States, 2 in Israel, and 1
in Denmark (designated “European centers”). During
1994 and 1995, 870 patients were randomized to either
high-dose aprotinin (Hammersmith regimen) or place-
bo. The outcome of this study was eventually reported
2 years later at the Seventy-eighth Annual Meeting of
The American Association for Thoracic Surgery (1998)
in Boston.15 Only 703 patients (80%) had satisfactory
graft angiograms. The studies showed thrombotic
occlusion in 15.4% of aprotinin-treated patients versus
10.9% in the placebo group (P = .03). Given the signif-
icant increase in vein graft occlusion for aprotinin-treat-
ed patients, the whole population was subject to rigorous
subanalysis. From this, Bayer reported “a significant
treatment by site interaction for one of the non-US sites
vs the US centers. When the analysis of graft closures
was repeated for US centers only, there was no statisti-
cally significant difference in graft closure rates in
patients who received Trasylol vs placebo.”16
This conclusion from the Bayer advertising literature
is open to discussion. Why were the differences in vein
graft occlusion rates between US and non-US centers so
dramatic (aprotinin: non-US 23%, US 9.4%; placebo:
non-US 12.4%, US 9.5% (Table I)? Should aprotinin or
the surgeons be blamed? Scrutiny of the data provides
several explanations. The study protocol was changed
at 1 Israeli site after blood for vein preparation was ini-
tially obtained from the central venous line into which
the aprotinin had been administered. Remarkably, this
A protinin therapy is now advocated by some enthusi-asts to inhibit fibrinolysis and preserve platelet
function in patients undergoing coronary artery bypass
grafting (CABG). In these patients ischemia during har-
vesting and preparation of the saphenous vein already
impairs endothelial cell anticoagulant function (Fig 1),
the protease enzyme components of which are then
inhibited by aprotinin.1,2 In every other branch of
surgery, fibrinolysis is regarded as a vital physiologic
process to maintain blood vessel patency in the face of
surgically induced thrombin formation. Similarly, in
patients with coronary artery disease, aspirin is pre-
scribed to impair platelet adhesion.3 Can this paradox be
rationalized? Should aprotinin be used in coronary
surgery?
Trials of aprotinin during CABG operations have
raised important issues regarding both heparin manage-
ment and graft patency.4-6 In the United States, 3 con-
secutive randomized trials reported excess mortality and
myocardial infarction when less than the full-dose apro-
tinin regimen was used in primary or reoperative coro-
nary operations.7-9 In some patients, autopsy showed
occlusion of the native coronary arteries in contrast to
the vein grafts.7 Inasmuch as these trials were designed
to confirm the blood-sparing effect, they were individu-
ally too small to determine the safety issues. Because of
this, Smith and Muhlbaier10 pooled raw data for patients
undergoing CABG from 6 trials and documented a 42%
increase in observed CABG mortality in patients sub-
jected to the half-dose regimen. The authors concluded
that aprotinin was safe and effective only with the full-
dose regimen. The effects on graft patency remained to
be determined.
Studies of vein graft patency have produced conflict-
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produced a graft occlusion rate of 73% in the aprotinin
group and an important indication of the risk of this
agent in patients with coronary disease. After proce-
dures at this center had been revised, graft occlusion
rates with aprotinin decreased to 14% versus 3% for
placebo for the remaining two thirds of the study. There
were other important differences (Table I). First, the
patients were selected, not consecutive, and the coro-
nary surgery intervention rates in the United States
(>1000 · 106) greatly exceed those of European centers
(<500 · 106). Despite this, the US centers randomized
on average only 47 patients over 2 years, of whom 90%
were male. One center randomized only 2 patients.
Patients in US centers had larger and better-quality dis-
tal vessels. The US sites also had a higher proportion of
patients receiving aspirin within 2 days of the opera-
tion, which could favor graft patency. Consequently,
the US patient cohort was less likely to have graft occlu-
sion with or without aprotinin. In contrast, European
centers randomized an average of 133 patients per cen-
ter, more women, more patients with vessels less than
1.5 mm in diameter, and more with distal disease. These
variables were identified as predisposing to graft occlu-
sion in aprotinin-treated patients, and certainly the dif-
ference in occlusion rates for women and those with
less than satisfactory distal vessels was substantial
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Fig 1. The anticoagulant function of the endothelial cell acts to prevent intravascular thrombosis. During surgery,
thrombin generation through activation of the coagulation cascade stimulates the endothelial cell (via thrombo-
modulin and heparan sulphate receptors) to release anticoagulants. The endothelium initiates activation of factor
VII by tissue factor (the most potent initiator of coagulation known) and produces thrombomodulin, which is
reduced by 30% during vein harvest. Binding of antithrombin III inactivates thrombin while tissue plasminogen
activator (T.P.A.) triggers fibrinolysis and protein C inhibits coagulation. These enzymes are down-regulated by
the nonspecific protease inhibitor aprotinin.
Table I. Comparison between US and non-US centers
Patients with SVG angiographically investigated (n = 703)
All study patients (n = 870) Aprotinin Placebo
Site Mean/ Male Occlusion*/ Occlusion*
(No. of centers) Total center Range (%) total Percent† /total Percent† P
US (10) 471 47 2-95 90 19/202 9.4 17/179 9.5 .72
Non-US (3) 399 133 105-168 85 37/161 23 20/161 12.4 .01
SVG, Saphenous vein graft.
*Calculated from provided occlusion rate and group size in Table IV.15
†By-patient occlusion rate.
(Table II). Vessel measurement is an inexact science and
coronary angiography can underestimate native vessel
size in the presence of a high-grade proximal stenosis or
occluded vein graft. Some vessels said to be less than
1.5 mm may well have been larger.
Bayer’s interpretation that aprotinin does not pro-
mote vein graft occlusion in the United States is over-
ly simplistic.16 Given the dramatic increase in inter-
ventional cardiology (since 1995) for patients with
discrete lesions and good distal vessels, the vast major-
ity of surgical candidates now have 1 or more coronary
arteries with “high-risk” characteristics. Those ran-
domized in the non-US centers now better represent the
global CABG population and, from this study, are
clearly at risk from aprotinin therapy during CABG.15
Although there was no significant difference in periop-
erative myocardial infarction rates, the incomplete
revascularization resulting from early graft occlusion
predisposes the patient to late myocardial infarction,
recurrent angina, and reduced event-free survival.
Occluded CABGs are a high price to pay for an aver-
age blood saving of 250 mL, particularly inasmuch as
excessive pump prime volume, as well as blood loss,
determines the postoperative hematocrit value in most
straightforward operations. There are other ways to
conserve blood, and the contrary view that hemodilu-
tion, temporary fibrinolysis, and platelet dysfunction
convey benefit by promoting vein graft patency is more
appealing.
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Table II. Observed “by-graft” occlusion rates and risk for designated high-risk variables
Occlusion rates (%)
Variables Aprotinin Placebo P* Adjusted risk ratio 90% CL
Female patients 20.7 4.2 .06 5.34 1.81-15.80
Distal vessel ≤ 1.5 mm 10.8 5.3 .06 1.92 1.15-3.20
Poor distal vessel 11.4 5.5 .08 1.90 1.09-3.32
CL, Confidence limits.
*To drug-by-covariate interaction.
